Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450080 | 0.88 | L3MBTL1 (0.39) | PDE10AL3MBTL1KCNH2NPC1RAB9A | |
| SCHEMBL14164716 | 0.83 | TLR7 (0.37) | PDE10AKCNH2ALDH1A1POLB | |
| SCHEMBL6998356 | 0.82 | ALDH1A1 (0.40) | KCNH2NPC1RAB9ARECQLKDM4E | |
| SCHEMBL22291045 | 0.81 | L3MBTL1 (0.39) | PDE10AL3MBTL1NPC1RAB9AKDM4E | |
| SCHEMBL19347319 | 0.79 | NUDT1 (0.50) | PDE10AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7083481 | 0.77 | CRHR1 (0.41) | — | |
| SCHEMBL20595996 | 0.77 | KDM4E (0.43) | L3MBTL1RAB9ARECQLKDM4EALDH1A1 | |
| SCHEMBL2179459 | 0.77 | L3MBTL1 (0.41) | L3MBTL1NPC1RAB9AROCK1KDM4E | |
| Bromide SCHEMBL17873904 | 0.75 | L3MBTL1 (0.40) | L3MBTL1NPC1RAB9AROCK1KDM4E | |
| SCHEMBL24963642 | 0.73 | TNKS (0.36) | PDE10AL3MBTL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772249-B2 | Imidazo[1,2-b]pyridazine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6589952-B2 | Imidazo(1,2-a)pyrazines containing an aryl or heteroaryl group are useful as (corticotropin releasiang factor) CRF receptor antagonists in the treatment of various neurological and psychological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| EP-1301511-A2 | IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
| WO-2002006286-A2 | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | PDE10A 1312/4885L3MBTL1 3734/4885KCNH2 1084/4885 |
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | SCN5A, HRH2, CHRNA5 | PDE10A 2065/4885L3MBTL1 4682/4885KCNH2 417/4885 |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | PDE10A 1312/4885L3MBTL1 3734/4885KCNH2 1084/4885 |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | CRHR1, CRHR2, CRH | PDE10A 1214/4885L3MBTL1 4396/4885KCNH2 2254/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | PDE10A 1783/4885L3MBTL1 3135/4885KCNH2 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.